• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗病毒 T 淋巴细胞反应的极性和特异性决定了癌症患者和健康个体对 SARS-CoV-2 感染的易感性。

The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals.

机构信息

Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.

Gustave Roussy, Villejuif, France.

出版信息

Cancer Discov. 2022 Apr 1;12(4):958-983. doi: 10.1158/2159-8290.CD-21-1441.

DOI:10.1158/2159-8290.CD-21-1441
PMID:35179201
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9394394/
Abstract

UNLABELLED

Vaccination against coronavirus disease 2019 (COVID-19) relies on the in-depth understanding of protective immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We characterized the polarity and specificity of memory T cells directed against SARS-CoV-2 viral lysates and peptides to determine correlates with spontaneous, virus-elicited, or vaccine-induced protection against COVID-19 in disease-free and cancer-bearing individuals. A disbalance between type 1 and 2 cytokine release was associated with high susceptibility to COVID-19. Individuals susceptible to infection exhibited a specific deficit in the T helper 1/T cytotoxic 1 (Th1/Tc1) peptide repertoire affecting the receptor binding domain of the spike protein (S1-RBD), a hotspot of viral mutations. Current vaccines triggered Th1/Tc1 responses in only a fraction of all subject categories, more effectively against the original sequence of S1-RBD than that from viral variants. We speculate that the next generation of vaccines should elicit Th1/Tc1 T-cell responses against the S1-RBD domain of emerging viral variants.

SIGNIFICANCE

This study prospectively analyzed virus-specific T-cell correlates of protection against COVID-19 in healthy and cancer-bearing individuals. A disbalance between Th1/Th2 recall responses conferred susceptibility to COVID-19 in both populations, coinciding with selective defects in Th1 recognition of the receptor binding domain of spike. See related commentary by McGary and Vardhana, p. 892. This article is highlighted in the In This Issue feature, p. 873.

摘要

未加标签

针对 2019 年冠状病毒病(COVID-19)的疫苗接种依赖于对严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)的保护性免疫反应的深入了解。我们对针对 SARS-CoV-2 病毒裂解物和肽的记忆 T 细胞的极性和特异性进行了表征,以确定与无疾病和癌症个体中 COVID-19 的自发、病毒引发或疫苗诱导保护相关的因素。1 型和 2 型细胞因子释放失衡与 COVID-19 的高易感性相关。易感染的个体表现出针对辅助性 T 细胞 1/细胞毒性 T 细胞 1(Th1/Tc1)肽库的特定缺陷,影响刺突蛋白(S1-RBD)的受体结合域,这是病毒突变的热点。当前的疫苗仅在部分受试者类别中引发 Th1/Tc1 反应,对 S1-RBD 的原始序列的效果比病毒变异体更好。我们推测,下一代疫苗应该针对新兴病毒变异体的 S1-RBD 域引发 Th1/Tc1 T 细胞反应。

意义

本研究前瞻性分析了健康和癌症个体中针对 COVID-19 的病毒特异性 T 细胞保护相关因素。在这两种人群中,Th1/Th2 回忆反应的失衡赋予了 COVID-19 的易感性,同时伴随着 Th1 对刺突受体结合域的识别出现选择性缺陷。请参阅 McGary 和 Vardhana 的相关评论,第 892 页。本文在本期特色文章中重点介绍,第 873 页。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb56/9394394/c39b7c788736/958fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb56/9394394/f7d4cb8b5a7d/958fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb56/9394394/2af58aa6432e/958fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb56/9394394/b6e32e2836d9/958fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb56/9394394/19c5dba79089/958fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb56/9394394/c39b7c788736/958fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb56/9394394/f7d4cb8b5a7d/958fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb56/9394394/2af58aa6432e/958fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb56/9394394/b6e32e2836d9/958fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb56/9394394/19c5dba79089/958fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb56/9394394/c39b7c788736/958fig5.jpg

相似文献

1
The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals.抗病毒 T 淋巴细胞反应的极性和特异性决定了癌症患者和健康个体对 SARS-CoV-2 感染的易感性。
Cancer Discov. 2022 Apr 1;12(4):958-983. doi: 10.1158/2159-8290.CD-21-1441.
2
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.新型冠状病毒刺突蛋白受体结合域线性表位在 COVID-19 mRNA 疫苗接种者中的高分辨率线性表位作图。
Microbiol Spectr. 2021 Dec 22;9(3):e0096521. doi: 10.1128/Spectrum.00965-21. Epub 2021 Nov 10.
3
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.全面描述了针对 SARS-CoV-2 刺突蛋白的抗体反应,发现了除轻度感染诱导的表位之外的其他疫苗诱导的表位。
Elife. 2022 Jan 24;11:e73490. doi: 10.7554/eLife.73490.
4
RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies.RBD 特异性 Th1 反应与血液恶性肿瘤患者接种疫苗后预防 SARS-CoV-2 感染有关。
Oncoimmunology. 2023 Jan 4;12(1):2163785. doi: 10.1080/2162402X.2022.2163785. eCollection 2023.
5
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
6
Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.mRNA 疫苗接种后针对 SARS-CoV-2 变体 RBD 的中和抗体反应减弱和异质性。
Front Immunol. 2022 Apr 6;13:816389. doi: 10.3389/fimmu.2022.816389. eCollection 2022.
7
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.一种糖基化 RBD 蛋白诱导针对奥密克戎和其他变体的增强型中和抗体,提高对 SARS-CoV-2 感染的保护作用。
J Virol. 2022 Sep 14;96(17):e0011822. doi: 10.1128/jvi.00118-22. Epub 2022 Aug 16.
8
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.一种针对严重急性呼吸综合征冠状病毒 2 刺突蛋白 RBD 的疫苗可诱导保护性免疫。
Nature. 2020 Oct;586(7830):572-577. doi: 10.1038/s41586-020-2599-8. Epub 2020 Jul 29.
9
Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.中和 SARS-CoV-2 需要针对构象受体结合域表位的抗体。
Allergy. 2022 Jan;77(1):230-242. doi: 10.1111/all.15066. Epub 2021 Sep 22.
10
Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2.靶向刺突糖蛋白的细胞毒性 T 细胞与 SARS-CoV-2 的混合免疫有关。
J Immunol. 2023 May 1;210(9):1236-1246. doi: 10.4049/jimmunol.2200815.

引用本文的文献

1
Clinical impact of concurrent autologous adoptive T cells immunotherapy in active COVID-19 infected cancer patients for chemotherapy.同期自体过继性T细胞免疫疗法对正在接受化疗的活动性新冠病毒感染癌症患者的临床影响。
Infect Agent Cancer. 2025 Apr 9;20(1):23. doi: 10.1186/s13027-025-00654-2.
2
Comprehensive analyses of immune activity in COVID-19-vaccinated idiopathic pulmonary fibrosis patients.对接种新冠疫苗的特发性肺纤维化患者免疫活性的综合分析。
Front Immunol. 2025 Jan 8;15:1436491. doi: 10.3389/fimmu.2024.1436491. eCollection 2024.
3
Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic Malignancies.

本文引用的文献

1
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study.癌症患者接种疫苗后对 SARS-CoV-2 关注变体的适应性免疫和中和抗体:CAPTURE 研究。
Nat Cancer. 2021 Dec;2:1321-1337. doi: 10.1038/s43018-021-00274-w. Epub 2021 Oct 27.
2
High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2.高个体中和活性对原始株及 9 种不同 SARS-CoV-2 变异株的异质性。
Viruses. 2021 Oct 28;13(11):2177. doi: 10.3390/v13112177.
3
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2.
尽管在血液恶性肿瘤中进行了全面疫苗接种,但针对 SARS-CoV-2 奥密克戎变体的免疫功能仍存在缺陷。
Blood Cancer Discov. 2023 May 1;4(3):172-175. doi: 10.1158/2643-3230.BCD-22-0213.
4
RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies.RBD 特异性 Th1 反应与血液恶性肿瘤患者接种疫苗后预防 SARS-CoV-2 感染有关。
Oncoimmunology. 2023 Jan 4;12(1):2163785. doi: 10.1080/2162402X.2022.2163785. eCollection 2023.
5
Conserved longitudinal alterations of anti-S-protein IgG subclasses in disease progression in initial ancestral Wuhan and vaccine breakthrough Delta infections.在最初的武汉原始毒株感染和疫苗突破性德尔塔毒株感染的疾病进展过程中,抗S蛋白IgG亚类的保守纵向变化。
Front Microbiol. 2022 Nov 22;13:1043049. doi: 10.3389/fmicb.2022.1043049. eCollection 2022.
6
Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice.扩展的严重急性呼吸综合征冠状病毒2受体结合域加强疫苗接种可诱导小鼠产生体液和细胞免疫耐受。
iScience. 2022 Dec 22;25(12):105479. doi: 10.1016/j.isci.2022.105479. Epub 2022 Nov 2.
7
SARS-CoV-2 in immunocompromised individuals.免疫功能低下个体中的 SARS-CoV-2。
Immunity. 2022 Oct 11;55(10):1779-1798. doi: 10.1016/j.immuni.2022.09.006. Epub 2022 Sep 13.
8
SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders.SARS-CoV-2 暴露前预防:一种针对高危人群(包括医护人员、免疫功能低下个体和疫苗应答不良者)的 COVID-19 潜在预防策略。
Front Public Health. 2022 Aug 8;10:945448. doi: 10.3389/fpubh.2022.945448. eCollection 2022.
9
Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study.外周血淋巴细胞亚群计数可预测癌症患者接种 SARS-CoV-2 mRNA-BNT162b2 疫苗后的抗体反应:来自 Vax-On-Profile 研究的结果。
Int Immunopharmacol. 2022 Jul;108:108774. doi: 10.1016/j.intimp.2022.108774. Epub 2022 Apr 14.
预先存在的聚合酶特异性 T 细胞在 SARS-CoV-2 无血清学阴性中扩增。
Nature. 2022 Jan;601(7891):110-117. doi: 10.1038/s41586-021-04186-8. Epub 2021 Nov 10.
4
Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.异源 ChAdOx1-BNT162b2 疫苗接种的免疫原性和疗效。
Nature. 2021 Dec;600(7890):701-706. doi: 10.1038/s41586-021-04120-y. Epub 2021 Oct 21.
5
Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting.BNT162b2mRNA 新冠疫苗在全国大规模疫苗接种环境中对血液系统恶性肿瘤患者的有效性。
Blood. 2022 Mar 10;139(10):1439-1451. doi: 10.1182/blood.2021013768.
6
Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anticancer therapy.恶性肿瘤患者 SARS-CoV2-IgG 血清转化模式及其与抗癌治疗的关系。
Nat Cancer. 2021 Apr;2(4):392-399. doi: 10.1038/s43018-021-00191-y. Epub 2021 Mar 22.
7
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.成年人实体瘤中接受两剂和三剂 BNT162b2 mRNA 疫苗的免疫反应。
Nat Med. 2021 Nov;27(11):2002-2011. doi: 10.1038/s41591-021-01542-z. Epub 2021 Sep 30.
8
COVID-19 Vaccines in Cancer Patients. Seropositivity and Safety. Systematic Review and Meta-Analysis.癌症患者中的新冠病毒疫苗。血清阳性率与安全性。系统评价与荟萃分析。
Vaccines (Basel). 2021 Sep 20;9(9):1048. doi: 10.3390/vaccines9091048.
9
Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors.BNT162b2 免疫接种 SARS-CoV-1 幸存者中的泛沙贝科病毒中和抗体。
N Engl J Med. 2021 Oct 7;385(15):1401-1406. doi: 10.1056/NEJMoa2108453. Epub 2021 Aug 18.
10
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.新冠疫苗突破性感染在已接种疫苗的医护人员中发生。
N Engl J Med. 2021 Oct 14;385(16):1474-1484. doi: 10.1056/NEJMoa2109072. Epub 2021 Jul 28.